The landscape of medical treatment has evolved significantly with the development of programs that allow patients access to investigational drugs before they receive full regulatory approval. These initiatives have become essential pathways for individuals facing life-threatening conditions who have exhausted all available treatment options. Through various mechanisms operating under different names across the globe, pharmaceutical companies and regulatory agencies have created structured frameworks that balance patient need with scientific rigor and safety considerations.
Understanding Expanded Access and Compassionate Use
Expanded access programs, often referred to as compassionate use, represent a critical bridge between clinical trials and full market approval for investigational medicines. These programs allow patients with serious or immediately life-threatening diseases to obtain treatments that are still undergoing the approval process. The foundation of these programs dates back to the late 1970s in the United States, with formal regulations established in 1987 largely in response to the HIV/AIDS crisis when patients desperately sought access to experimental treatments.
Between 2005 and 2014, the FDA’s Center for Drug Evaluation and Research received 10,939 new expanded access applications, with the number of requests more than doubling from 2005 to 2014. This significant increase demonstrates the growing awareness and utilization of these programs among physicians and patients. From fiscal year 2012 through 2015, the FDA received nearly 5,800 expanded access requests and allowed 99 percent to proceed, highlighting the program’s effectiveness in facilitating patient access while maintaining appropriate oversight.
Named Patient Programs and Global Variations
The terminology and structure of investigational drug access programs vary considerably across different regions and regulatory jurisdictions. Named patient programs, particularly common in Europe and Asia Pacific regions, allow physicians to request specific unapproved medications for individual patients facing critical situations. As mentioned by Early Access Care (https://earlyaccesscare.com/services/named-patient-programs), “these programs provide ethical and compliant mechanisms for accessing investigational treatments when standard therapies are unavailable or unsuitable.”
In Japan, expanded access clinical trials were established in January 2016, focusing on investigational products in the final stages of clinical trials before marketing authorization. Different countries use various terms including Special Access Scheme in Australia, Temporary Authorization for Use in France, and Early Access to Medicines Scheme in the United Kingdom. Despite the diverse nomenclature, these programs share common objectives: providing treatment options to patients with unmet medical needs while ensuring appropriate regulatory oversight.
Types of Expanded Access Mechanisms
The majority of expanded access applications are for single patient use, split almost evenly between emergency and non-emergency situations. Single patient expanded access represents the most personalized form of these programs, where a physician applies on behalf of an individual patient who cannot participate in clinical trials or has no other treatment alternatives. Emergency access can be authorized rapidly, often within hours, when immediate treatment is necessary to preserve life or prevent serious deterioration of health.
Intermediate-size population programs serve more than one patient but are typically employed when the investigational drug is not actively being developed for marketing approval. Treatment protocols, the broadest category, allow for widespread use of investigational drugs that are in later stages of development and have demonstrated sufficient evidence of safety and effectiveness. Of 92 expanded access programs examined, approximately 70 percent were initiated just before or after new drug application submission, indicating that most programs begin when substantial clinical data already exists.
The Application Process and Stakeholder Responsibilities
Accessing investigational drugs through these programs requires coordination among multiple parties. The treating physician must initiate the request, demonstrating that potential benefits outweigh risks for the specific patient. The pharmaceutical manufacturer must agree to provide the investigational product, which is not guaranteed despite regulatory approval. Almost 96 percent of expanded access requests submitted between fiscal year 2012 and 2015 were for single patients, reflecting the individualized nature of most applications.
The process also typically requires institutional review board approval to ensure patients are fully informed about the experimental nature of the treatment and associated risks. The FDA or relevant regulatory authority then reviews the request to determine whether proceeding is appropriate. The FDA authorized 99 percent of single patient expanded access applications during fiscal years 2010 through 2015, demonstrating regulatory willingness to facilitate access when appropriate criteria are met.
Benefits Beyond Individual Patient Treatment
These programs serve purposes beyond helping individual patients access potentially life-saving treatments. Data collected from expanded access use can contribute valuable information about drug safety and effectiveness in real-world populations that may differ from clinical trial participants. Patients receiving investigational drugs through compassionate use programs are often more critically ill or have more advanced disease than those enrolled in controlled trials, providing insights into how medications perform under challenging conditions.
Only two drug development programs out of nearly 11,000 expanded access requests over ten years were placed on clinical hold due to adverse events observed during expanded access, and even these were temporary. This remarkably low rate challenges the concern sometimes raised by manufacturers that adverse events during expanded access might jeopardize overall drug development programs. The data demonstrates that regulatory authorities evaluate adverse events within their appropriate context, recognizing differences between expanded access populations and clinical trial participants.
Challenges and Considerations
Despite high approval rates, several challenges persist in expanded access programs. Manufacturers may decline to provide investigational drugs for legitimate reasons including limited drug supplies, concerns about diverting eligible patients from clinical trials, or unfavorable risk-benefit profiles in specific populations. Physicians may be reluctant to navigate what can be a complex and time-consuming application process, particularly given they are typically uncompensated for this work.
Cost presents another significant barrier. Patients are often responsible for paying for their expanded access treatment out of pocket, as manufacturers are not obligated to provide drugs at no cost and most insurance programs do not cover experimental treatments. The lack of established efficacy adds further complexity to decision-making. According to FDA data, at least one-third of phase I drugs are withdrawn for safety concerns, and only about one-fifth ultimately receive approval, underscoring the experimental nature of these treatments.
Final Word
Programs providing access to investigational drugs have fundamentally enhanced treatment possibilities for patients facing serious or life-threatening conditions without satisfactory alternatives. Through various mechanisms operating globally under names including expanded access, compassionate use, and named patient programs, these initiatives have created structured pathways that respect both patient needs and scientific principles. The impressive approval rates, minimal impact on drug development programs, and growing utilization demonstrate that regulatory systems have successfully balanced facilitating patient access with protecting public health. As awareness continues to grow and processes become more streamlined, these programs will likely play an increasingly important role in modern medicine, offering hope to those who cannot wait for traditional approval timelines.
